Sinovac Biotech (北京科兴生物制品有限公司) released an early report from the clinical trial of its A/H1N1 influenza vaccine, announcing that no severe adverse reactions were observed following the first inoculation. Participants experienced an 11.8% rate of adverse reactions. That is approximately equal to the average vaccine reaction and consisted mainly of pain at the injection site. More details...

Stock Symbol: (NYSE AMEX: SVA)